Essential Wegovy Comparison Guide for First-Time Users
Wegovy Comparison: Understanding Your Starter Dose Options
When comparing Wegovy and Mounjaro starter doses, the most significant difference lies in their dosing philosophy and mechanism. Wegovy begins at 0.25mg weekly for the first four weeks, representing the gentlest introduction to GLP-1 therapy available in the UK. This ultra-low starter dose allows your body to gradually adapt to semaglutide's appetite-suppressing effects, minimising the risk of gastrointestinal side effects that can occur when starting weight management injections. Mounjaro, by contrast, starts at 2.5mg weekly—a substantially higher initial dose reflecting tirzepatide's dual-hormone approach.
This Wegovy comparison reveals why many prescribers favour Wegovy's starter dose for patients new to injectable weight management treatments. The 0.25mg introduction phase gives you time to establish injection routines, monitor your body's response, and adjust eating patterns gradually. EverydayMeds supplies this starter dose for £79.99, covering your first month while you determine treatment tolerance. The careful escalation protocol—moving to 0.5mg in weeks 5-8, then 1mg in weeks 9-12—ensures optimal therapeutic progression without overwhelming your system with sudden hormonal changes.
Starter Dose Pricing and Value in Our Wegovy Comparison
Our comprehensive Wegovy comparison includes transparent pricing for both starter doses and progression bundles. Wegovy's 0.25mg starter dose costs £79.99 for new customers using code FIRST40 at checkout, while the equivalent Mounjaro 2.5mg starter dose is priced at £139.99. For patients planning ahead, our Intro Duo bundle combines Wegovy's first two doses (0.25mg and 0.5mg) for £169.99, providing seamless progression through weeks 1-8. This compares favourably to purchasing doses separately and ensures continuity of supply during your critical adjustment period.
The financial advantage extends beyond individual pen pricing in this Wegovy comparison. Wegovy's storage stability allows 6 weeks at room temperature once removed from the fridge, compared to Mounjaro's 21-day limit—reducing replacement costs from temperature excursions. Returning customers benefit from code DOSE25 for ongoing orders, while our Take-It-Slow bundles accommodate patients requiring extended time at each dose level. The Gentle Start Trio (two 0.25mg pens plus one 0.5mg) costs £269.99, perfect for patients preferring an 8-week introduction phase before dose escalation.
Clinical Evidence Supporting This Wegovy Comparison
The STEP clinical trial programme provides robust evidence for Wegovy's starter dose effectiveness in our comparison analysis. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with the gentle dose escalation beginning at 0.25mg weekly (Wilding et al., NEJM, 2021). The trial demonstrated that this conservative starter dose approach maintained excellent tolerability while achieving clinically meaningful outcomes. The gradual introduction protocol resulted in lower discontinuation rates compared to more aggressive dosing strategies.
Mounjaro's clinical evidence from the SURMOUNT trials shows different starter dose dynamics in this Wegovy comparison. The 2.5mg weekly starting dose, while higher than Wegovy's 0.25mg, reflects tirzepatide's dual GIP and GLP-1 receptor agonism requiring different therapeutic initiation. Both treatments demonstrate significant efficacy when prescribed appropriately, but the starter dose tolerance profiles vary between patient populations. Your prescriber will consider factors including previous medication sensitivity, weight management history, and individual risk factors when determining which starter dose aligns with your treatment goals.
Mechanism Differences in Our Wegovy Comparison
Understanding how these treatments work reveals crucial insights for this Wegovy comparison at the starter dose level. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural glucagon-like peptide-1 hormone to reduce appetite and promote satiety after smaller meals. From the very first 0.25mg injection, Wegovy begins influencing brain appetite centres and slowing gastric emptying, creating gradual changes in eating patterns. The single-hormone approach provides targeted, predictable effects that build systematically as doses increase over 16 weeks. This mechanism explains why even the low 0.25mg starter dose can produce noticeable appetite reduction within days of administration, though full therapeutic effects develop over several months of treatment.
Ordering Process for Both Options in This Wegovy Comparison
EverydayMeds streamlines access to both treatments featured in this Wegovy comparison through our efficient clinical pathway. Begin with our 3-minute online clinical assessment covering medical history, current medications, and weight management goals—the same process applies whether you're considering Wegovy or Mounjaro starter doses. Our UK-registered prescribers review applications within 3 working days (or 24 hours with express service), determining the most appropriate starter dose based on your individual circumstances. Once approved, your prescription ships via next-day delivery using temperature-controlled packaging to preserve medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all treatments meet stringent UK pharmaceutical standards from manufacture to doorstep delivery.
Storage and Practical Considerations in This Wegovy Comparison
Practical storage differences significantly impact real-world use in this Wegovy comparison, particularly for starter dose patients still adapting to injection routines. Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, but Wegovy offers superior room temperature stability—remaining effective for 6 weeks below 30°C once removed from the fridge. This advantage proves invaluable during travel, power outages, or temporary storage issues that commonly affect patients beginning their weight management journey. The FlexTouch pen delivery system used for Wegovy provides intuitive dose administration with clear click confirmation, while Mounjaro employs KwikPen technology with similar user-friendly features. Both starter doses require weekly injection timing, but the mandatory dose escalation schedules differ significantly—Wegovy's 16-week progression versus Mounjaro's alternative timeline.
Why Starter Dose Choice Matters in Wegovy Comparison
The starter dose decision proves pivotal in this Wegovy comparison because it establishes your entire treatment trajectory and tolerance foundation. Wegovy's ultra-conservative 0.25mg beginning allows maximum flexibility for patients with sensitive stomachs, previous medication intolerances, or anxiety about injection therapy. Many patients find this gentle introduction builds confidence while minimising common side effects like nausea or reduced appetite that might otherwise compromise treatment adherence. The four-week stabilisation period at each dose level provides ample opportunity to establish sustainable lifestyle changes alongside pharmaceutical intervention.
Conversely, Mounjaro's higher 2.5mg starter dose reflects its dual-hormone mechanism requiring different therapeutic initiation in this Wegovy comparison. Some patients prefer this approach for faster initial effects, though individual responses vary significantly. The choice ultimately depends on your medical history, tolerance preferences, and prescriber recommendation. Both treatments demonstrate excellent efficacy when used appropriately, making the starter dose decision more about optimising your personal treatment experience than comparing superior effectiveness between options.
Making Your Decision: Complete Wegovy Comparison Summary
This comprehensive Wegovy comparison demonstrates that both treatments offer distinct advantages for different patient populations, particularly at the crucial starter dose phase. Wegovy's 0.25mg beginning provides the gentlest possible introduction to GLP-1 therapy at £79.99, while Mounjaro's 2.5mg starter dose offers dual-hormone benefits from the outset at £139.99. Both are available through EverydayMeds with identical clinical assessment processes, next-day delivery, and ongoing prescriber support throughout your weight management journey. Your individual medical circumstances, tolerance preferences, and treatment goals should guide this decision in consultation with qualified healthcare professionals. Use code FIRST40 for new customer pricing on your chosen starter dose, or DOSE25 for returning customer benefits. Visit https://everydaymeds.co.uk/products/wegovy-0-25mg to begin your clinical assessment today, supported by our experienced clinical team and GPhC-registered pharmacy services (#9012878) ensuring safe, effective treatment initiation.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
